AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” press release.

3 February 2021

Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks

19 January 2021

EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed

15 January 2021

EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines

25 November 2020

Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

5 November 2020

Statement from the President: Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing

7 October 2020

Berlin, 07 October 2020, speaking at ‘For a Healthy Europe’, […]

COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy

9 July 2020

Urgent call for a structured industry-EU dialogue on reform The […]

EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from Covid19

4 June 2020

Letter to EU Trade Ministers. European Industry trade and supply chain needs to respond to Covid-19

10 April 2020

A statement from the President on COVID-19

8 April 2020